Talquetamab: A New GPRC5D Targeted Therapy On The Horizon image

Talquetamab: A New GPRC5D Targeted Therapy On The Horizon

Posted on: Jun 21, 2023

HealthTree University: Therapies On The Horizon - Talquetamab

Talquetamab is a bi-specific antibody that targets a specific GPRC5D antigen on myeloma cells, offering a promising alternative approach to treating multiple myeloma. Learn about the potential benefits it brings to patients. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole Therapies on the Horizon course at HealthTree University.

Talquetamab

 

We’d like to thank our faculty who donated their time in creating these videos, including:

  • Krina Patel, MD, MSc
  • Ravi Vij, MD, MBA

Want more?

We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!

 

Healthtree contact Clark Ahlstrom

Clark Ahlstrom

Clark Ahlstrom is the video team manager for HealthTree University and oversees video production of new HealthTree University videos. He started working at the foundation together with Jenny Ahlstrom, his mother, after her myeloma diagnosis.